AppZen Launches Autonomous Cards to Automate Enterprise Spend Compliance
AppZen introduces Autonomous Cards, an AI-powered spend intelligence layer that automates compliance and monitoring for enterprise card programs to improve financial oversight.
AppZen introduces Autonomous Cards, an AI-powered spend intelligence layer that automates compliance and monitoring for enterprise card programs to improve financial oversight.
CUJO AI introduces advanced residential proxy detection, enabling network operators to identify, classify, and remediate unauthorized device activity within subscriber homes.
Veeva Systems secures a major expansion as Servier adopts Veeva OpenData to standardize customer reference information across 80+ countries, bolstering Veeva's AI-ready…
SpendHQ introduces Savings Radar, an AI-powered solution that leverages procurement expertise and company-specific data to help teams identify and execute high-impact cost-saving…
The Cigna Group launches its 'Lead to One' vision, aiming to scale personalized health care services and leverage recent portfolio optimizations to…
ShopMy's new Spotlights feature integrates affiliate content with Meta and TikTok ad platforms, aiming to increase brand ad spend and campaign efficiency…
Seiko Epson supplies 84 high-performance 4K projectors for a major new AI-driven art installation, showcasing the firm's technical capabilities in large-scale visual…
Yonder Travel Insurance expands its comparison platform by adding Faye, providing travelers with increased access to modern, award-winning insurance coverage options.
Kenon Holdings expands its US energy footprint with a $450 million acquisition of a 25% stake in Vicinity District Energy, signaling a…
BestEx Research adds US equities to its pre-trade analytics suite, offering clients improved tools for portfolio construction and performance evaluation through multiple…
Cyware and WaterISAC launch a joint threat intelligence initiative to secure U.S. water infrastructure against evolving cyber threats using advanced AI-driven operational…
AbbVie's ABBV-295 shows promising Phase 1 results with a long half-life, enabling potential bi-weekly dosing and strengthening the company's metabolic drug pipeline.